How Did AbbVie's Immunology Franchise Fare in Q3?
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.